tiprankstipranks
Fulcrum Therapeutics (NASDAQ:FULC) Readies Phase 3 Candidate with Blockbuster Potential
PremiumMarket NewsFulcrum Therapeutics (NASDAQ:FULC) Readies Phase 3 Candidate with Blockbuster Potential
2M ago
Rubrik and Marex Group initiated: Wall Street’s top analyst calls
PremiumThe Fly
Rubrik and Marex Group initiated: Wall Street’s top analyst calls
2M ago
Cantor starts Fulcrum with Overweight ahead of Q4 data
PremiumThe Fly
Cantor starts Fulcrum with Overweight ahead of Q4 data
2M ago
Fulcrum Therapeutics upgraded to Buy from Neutral at Goldman Sachs
PremiumThe FlyFulcrum Therapeutics upgraded to Buy from Neutral at Goldman Sachs
2M ago
Fulcrum Therapeutics price target raised to $22 from $19 at Stifel
PremiumThe Fly
Fulcrum Therapeutics price target raised to $22 from $19 at Stifel
2M ago
Fulcrum Therapeutics sees cash runway into 2027
PremiumThe Fly
Fulcrum Therapeutics sees cash runway into 2027
2M ago
Fulcrum Therapeutics (FULC) Q1 Earnings Cheat Sheet
PremiumPre-EarningsFulcrum Therapeutics (FULC) Q1 Earnings Cheat Sheet
2M ago
Fulcrum announces publication of results on Phase 2b trial of losmapimod
PremiumThe Fly
Fulcrum announces publication of results on Phase 2b trial of losmapimod
3M ago
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
PremiumPress Releases
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100